Hashemi Bidokhti Mahnaz, Abbaszadegan Mohammad Reza, Sharifi Noorieh, Abbasi Sani Soodabeh, Forghanifard Mohammad Mahdi
Department of Biology, Damghan branch, Islamic Azad University, Damghan, Iran.; Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Ann Diagn Pathol. 2017 Apr;27:79-82. doi: 10.1016/j.anndiagpath.2017.01.010. Epub 2017 Feb 1.
Notch signaling pathway is involved in different cellular and developmental processes including cell proliferation, differentiation and apoptosis. Mastermind like1 (MAML1) is a critical key transcription coactivator of this pathway. In this study, we aimed to examine MAML1 protein expression in esophageal squamous cell carcinoma (ESCC) and reveal its association with clinicopathological variables of the patients.
Tumoral and their margin normal tissues from 56 ESCC patients were recruited for protein expression analysis using immunohistochemistry (IHC). Furthermore, MAML1 expression was analyzed in ESCC cell line KYSE-30 using immunocytochemistry.
Overexpression of MAML1 was detected in 59% of tumor samples. It was significantly associated with different indices of poor prognosis including depth of tumor invasion (P=0.026), grade of tumor differentiation (P=0.002), stage of tumor progression (P=0.004) and sex (P=0.027).
Beside the appearing evidences explaining MAML1 role in different cellular processes and its deviations in different malignancies and also based on its correlation with different clinicopathological variables of ESCC, MAML1 can be proposed as potentially novel molecular marker for ESCC progression and tumorigenesis as well as therapeutic target to inhibit and reverse progression and development of the disease.
Notch信号通路参与包括细胞增殖、分化和凋亡在内的不同细胞和发育过程。类主调控因子1（MAML1）是该通路的关键转录共激活因子。在本研究中，我们旨在检测食管鳞状细胞癌（ESCC）中MAML1蛋白的表达，并揭示其与患者临床病理变量的关系。
招募56例ESCC患者的肿瘤组织及其边缘正常组织，采用免疫组织化学（IHC）进行蛋白表达分析。此外，使用免疫细胞化学分析ESCC细胞系KYSE-30中的MAML1表达。
在59%的肿瘤样本中检测到MAML1过表达。它与不同的不良预后指标显著相关，包括肿瘤浸润深度（P=0.026）、肿瘤分化程度（P=0.002）、肿瘤进展阶段（P=0.004）和性别（P=0.027）。
除了已有证据解释MAML1在不同细胞过程中的作用及其在不同恶性肿瘤中的偏差，以及基于其与ESCC不同临床病理变量的相关性外，MAML1可被认为是ESCC进展和肿瘤发生的潜在新型分子标志物，也是抑制和逆转疾病进展和发展的治疗靶点。
